drugs
Navigation Links
drugs at medicine technology
Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
...cians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require laboratory support while many simple test kits are suitable...Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
...liver cells, they modify the chemical structure of drugs shortly after they are absorbed from the gastrointestinal tract. The chemical modification renders them more water soluble and hence more easily excreted. Six CYP enzymes (named 1A2, 2C9, 2C19, 2D6, 2E1, 3A4) account for over 90% of drug metabolism...Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal
...better, more individualized treatment methods than drugs designed to lower overall cholesterol levels. In fact, if treatment with an LDL-lowering drug (statins are the primary drug of choice) is unsuccessful, the NCEP recommends combining treatments, and referring the patient to a lipid specialist if this ...Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
...ution should beemployed when it is used with other drugs that affect hemostasis.The safety of AGGRASTATR when used in combination with thrombolyticagents has not been established. During therapy with AGGRASTATR,patients should be monitored for potential bleeding. When bleedingcannot be controlled with pres......aditionally been usedto accelerate the delivery of drugs and fluids, including localanesthetics, other co-i...ase theabsorption and dispersion of other injected drugs and fluids. TheCompany also has a number of different enzymes in its portfoliothat are targeting sig...CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
...ment and commercialization ofnovel, small molecule drugs for the treatment of cardiovasculardiseases. CV Therapeutics' approved product, Ranexa(R) (ranolazineextended-release tablets), is indicated for the treatment ofchronic angina in patients who have not achieved an adequateresponse with other antiangi...Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
...iabetic patients takingcholesterol-lowering statin drugs (Lipitor(R), Crestor(R) andZocor(R)) showed reduced levels of AtherOx complexes, suggestingthat these statins may also have a beneficial effect in loweringoxidative stress, a significant factor in atherosclerosis. An interim report was released on a......h other biological diseasemodifying anti-rheumatic drugs (DMARDs), serious infections havebeen reported in some patients treated with ACTEMRA. About Rheumatoid Arthritis Rheumatoid arthritis is a progressive, systemic autoimmunedisease characterized by inflammation of the membrane lining in thejoints. Th...Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease
...ience company focused oncommercializing innovative drugs to relieve the suffering ofpatients with Alzheimer...n's business strategy is to partner its laterstage drugs after Phase II (proof of concept) human studies and hasexecuted its first partnership for its PII, H......roprietary platform technology for the delivery of drugs into thehuman body through the oral cavity (with n...he Company's proprietary liquid formulations allow drugs typicallyadministered by injection to be absorbed into the body by thelining of the inner mouth usin......BikDD combination, the authorsreport. "All cancer drugs have some toxicity and so cause side effects,which affects the dose that can be administered," Hung says. Theteam looked for signs of acute systemic toxicity and ofpancreatitis, a dangerous inflammation of the pancreas. While thecytomegalovirus-BikDD......covery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases b...covery, development and commercialization of novel drugs toaddress some of the world's most widespread and costly chronicdiseases involving pathways in the l...Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
...nt and commercialization of targeted smallmolecule drugs to treat life-threatening and debilitating diseases.Our proprietary drug development pipeline is focused on thetreatment of cancer and inflammatory disease and includes clinicalcandidates that are designed to regulate therapeutically importanttargets...Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
...ization of novel orally-administeredsmall molecule drugs that modulate ion channel targets. Utilizingits proprietary know-how and integrated scientific and drugdevelopment capabilities, Icagen has identified multiple drugcandidates that modulate ion channels. The Company is conductingresearch and developme...Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
... company focused on the development and approvalof drugs for the treatment of metabolic diseases with unme...company focused on the developmentand approval of drugs for the treatment of metabolic diseaseswith unmet medical needs. For more information please visit&...... the incorporation of NexACT(R)into their existing drugs as a means of developing newpatient-friendly transdermal products and extending patentlifespans and brand equity. For further information about theCompany, go to www.nexmed.com. Statements under the Private Securities Litigation Reform Act:with th......f or the entire colon. Until recently, sales of UC drugs werearound US$1bn, dominated by 5-ASA drugs, corticosteroids andimmunosuppressants. However, with the introduction of the marketeddrug Remicade(r), total sales in this market segment have beengrowing substantially. About the Truelove-Witts and the M......ivaroxaban does not interact with awide variety of drugs that are commonly given concomitantly with ananticoagulant. To date, rivaroxaban is the most studied oral direct Factor Xainhibitor in development. More than 15,000 patients have beenevaluated in the completed Phase II programs and enrolled thus far......varoxaban does not interact with a wide variety of drugs that arecommonly given concomitantly with an anticoagulant. To date, rivaroxaban is the most studied oral direct Factor Xainhibitor in development. More than 15,000 patients have beenevaluated in the completed phase II programs and enrolled thus far...Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
...ion with 5-FU and other chemotherapy andbiological drugs for a superiority claim over the current standardo...Company's technology also is directed at"rescuing" drugs that were shelved for toxicity or "half-life"issues; increasing the solubility of existing drugs, an...Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
...rse,risk-sensitive portfolio of in-licensed cancer drugs to addressunmet medical needs. The Company applies new insights frommolecular and cancer biology to understand the efficacy and safetylimitations of approved and developmental cancer therapies andidentifies proprietary and related molecules for bette...Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
...h. Other pharmaceutical companies studying allergy drugs havereported problems with their clinical trials because of low symptomscores in an allergy season, with at least one report in ananalogous situation occurring in the 2006 ragweed season when weconducted our trials." The Company's chief executive of......om each of thethree major oral classes of anti-HIV drugs (NRTIs, NNRTIs, andPIs), unable to use currently a...he discovery anddevelopment of innovative HIV/AIDS drugs and anti-infectives fordiseases of high unmet medical need. About Tibotec Tibotec, a division of J......he discovery anddevelopment of innovative HIV/AIDS drugs and anti-infectives fordiseases of high unmet medical need. Tibotec Pharmaceuticals is developing a Global Access Program tofacilitate access to its antiretrovirals for patients living withHIV/AIDS in developing countries. The Global Access Program ...New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
... the potentialof receiving two investigational new drugs together to fight thedisease. The two drugs, among...efficacy trial for TMC125 (it is in a class of HIV drugs callednon-nucleoside reverse transcriptase inhibitors [NNRTI]). TheLancet study found that at the 24......e in formulating andmanufacturing gastrointestinal drugs for international clients atits GMP (Good Manufacturing Practice) facilities in Lainate, Italy.For further information on Cosmo, please visit the Company'swebsite: <a target="_blank" href="http://www.cosmopharmaceuticals.com/">www.cosmopharma......atment of breastcancer. Unfortunately, most of the drugs in the class havesignificant anti-glucocorticoid activity which would prohibit theirchronic use. In human studies conducted by Repros to date, Proellexhas exhibited little anti-glucocorticoid activity in humans. Proellex may represent a new approach...Avexa's Apricitabine Clinical Trial Update
...company with afocus on research and development of drugs for the treatment ofinfectious diseases, in partic...es andfunding for key projects including antiviral drugs for HIV and anantibiotic alternative for antibiotic-resistant bacterialinfections. The Company's lea......scovery, development and commercializationof novel drugs for acute cardiovascular and cancer therapy.Nuvelo's development pipeline includes three acute cardiovascularprograms: alfimeprase, a direct-acting fibrinolytic for thetreatment of thrombotic-related disorders; rNAPc2, an anticoagulantthat inhibits t...Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
...ore values, thestandard scale used to evaluate BPH drugs and treatments. Thisimprovement compares favorably...reported inpublished studies of currently approved drugs for BPH and reachedstatistical significance when compared to placebo. Subjects treatedwith NX-1207 a......ation or equivalent regulatory authorities, orthat drugs will be marketed successfully. Against the background ofthese uncertainties readers should not rely on forward-lookingstatements. The company assumes no responsibility to update forward-lookingstatements or adapt them to future events or developments...Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
...ladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib, cetuximab, panitumumab and others designed toblock overproduction of the epidermal growth factor receptor– but it is the most detailed analysis todate. The study, published in the July 1 issue of Clinical CancerResea......e right todevelop and commercialize biotherapeutic drugs for up to sixtargets. Genentech retains an option ...lopmentand commercialization of the biotherapeutic drugs that Lexicondevelops from the collaboration under a cost and profit sharingarrangement. ANGPTL4, ref......covery, development and commercialization of novel drugs inthe therapeutic areas of infection, cancer and inflammation. TheCompany's lead candidate, cethromycin, is a novel once-a-dayantibiotic in late-stage clinical development for the treatment ofrespiratory tract infections including CAP. For more infor...Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
...T inhibitors with a programme currently focused on drugs fortreatment of Parkinson's disease. In addition t...f L-DOPA replacement therapy. Theglobal market for drugs targeting Parkinson's disease was $1.7billion in 2003 and is forecast to grow substantially over the...Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
... Medicineto provide a reservoir for innovative new drugs for the globalpharmaceutical market.” En...r percent. The USmarket for Crohn’s Disease drugs was estimated to be US$590million, growing to around US$980 million by 2012. In bothcases, the glob......covery, development and commercialization of novel drugs inthe therapeutic areas of infection, cancer and inflammation. TheCompany's lead candidate, cethromycin, is a novel once-a-dayantibiotic in late-stage clinical development for the treatment ofrespiratory tract infections including CAP. For more infor......timizing the performance ofexisting small molecule drugs using its proprietarycontrolled-release technologies. The Company's lead product, aunique once-daily formulation of tramadol, is being commerciallylaunched in key markets globally. The Company has a robust pipelineof follow-on products in both pre-cl...RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
...ities and translating them into successfulmarketed drugs that target major unmet clinical needs in cancer,inflammation and neurodegenerative disease. The company's two leadprograms are entering advanced clinical trials for deadly,late-stage cancers. In parallel with its clinical development,Reata is advanc...Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
...e treatment of several tumortypes. However, these drugs have demonstrated limitedtreatment benefit against...her cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E andother mitotic kinesins may represent the next generation ofanti-mitot......ifficulty encountered thus far in the discovery of drugs thatwill inhibit this pathway without causing excessive toxicity. It isplausible that perifosine may be useful in combination to reducethe resistance to other cancer treatments. To date, over 1,500 patients have been treated with perifosinein trials...Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
... and commercialization of novel,mechanism-targeted drugs to treat human cancers and other seriousdisorders. Two Cyclacel drugs are in Phase II trials: sapacitabine(CYC682), an orally-available, cell cycle modulating nucleosidea......gs suggest that, since the effectivenessof the two drugs appears similar, physicians should consider sideef... trial that randomized the use of the pretermlabor drugs to compare outcome. Preterm labor is defined as labor before 37 weeks' gestation.Although it's not ......rse,risk-sensitive portfolio of in-licensed cancer drugs to addressunmet medical needs. The Company applies new insights frommolecular and cancer biology to understand the efficacy and safetylimitations of approved and developmental cancer therapies andidentifies proprietary and related molecules for bette...... for lupus patients iscritical because many of the drugs currently used to treat thedisease are toxic and can cause serious medical complications orside effects, sometimes worse than the disease itself. Preliminary data from the 24-week induction phase show thatCellCept achieved results that are equivalen......tments involve theoff-label use of existing cancer drugs such as cyclophosphamide,steroids, and immunosuppr...manifest itself when they are ofchild-bearing age, drugs that adversely affect fertility can alsocompound the negative impact of the disease on a patient's q......mising safety. Primus developsbranded prescription drugs and medical foods that are proven safeand effective in chronic or recurring diseases. The Company'sneeds-based process to develop first-line prescription productsformulated to restore metabolic processes at the disease source(rather than masking symp......re often prescribed non-steroidalanti-inflammatory drugs or NSAIDs, opioids, anticonvulsants, andantidepressants. About Avigen Avigen is a biopharmaceutical company focused on unique smallmolecule therapeutics and biologics to treat serious neurologicaldisorders, including neuropathic pain and neuromuscu...Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
... company focused on thedevelopment and approval of drugs for the treatment of metabolicdiseases with unmet ... company focused on the developmentand approval of drugs for the treatment of metabolic diseases withunmet medical needs. For more information, please visitw......cused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that ac...oping proprietary, orally available, smallmolecule drugs with the potential to treat diseases associated withaging, including metabolic diseases such as Type......1 levels. This studyprovides evidence that the two drugs may have complementary effectson GLP-1. "This is ...sitagliptin is excretedin human milk. Because many drugs are excreted in human milk, cautionshould be exercised when JANUVIA is administered to a nursing wom......biopharmaceuticalcompany developing small molecule drugs for the treatment ofgastrointestinal and metabolic...ts (TZP-101 and TZP-102)are promising breakthrough drugs with huge commercial potential.Most prokinetic agents under development and on the market act onpred...Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
...ndmarketing capabilities; the success of competing drugs that are orbecome available; and the performance of third party manufacturers.These and additional risks and uncertainties are described morefully in the Company's Form 10-K filed with the SEC under theSecurities Exchange Act of 1934. Copies of filin...HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
...keyliver-related function in the detoxification of drugs andxenobiotics. In contrast, HepG2-C3A showed very low or nodetectable P450 activity at all. (View HepaLife's April 10, 2007 press release and photographs:PICM-19 cells mimic liver's responses; significantly outperformmost widely-used liver cell lin......tide) injection BYETTA is the first in a class of drugs for the treatment oftype 2 diabetes called incretin mimetics. BYETTA exhibits many ofthe same effects as the human incretin hormone glucagon likepeptide-1 (GLP-1). GLP-1 improves blood sugar after food intakethrough multiple effects that work in conc......ination therapy with JANUVIA and metformin,the two drugs comprising JANUMET, over one year." An important ...sitagliptin is excretedin human milk. Because many drugs are excreted in human milk, cautionshould be exercised when JANUVIA is administered to a nursing wom......ping cell-basedalternatives to medical devices and drugs to treat and possiblycure numerous acute and chronic diseases. Additionally, PAConsulting Group, a global consulting firm with expertise in lifesciences and healthcare, estimates the worldwide market for mediato preserve cells, tissues, and organs f...Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
...s leftlargely unaffected by existing anti-platelet drugs such as aspirinand Plavix(TM). deCODE's medicinal...discoveriesin human genetics to the development of drugs and diagnostics forcommon diseases. deCODE is a global leader in gene discovery -- ourpopulation app......armaceutical company developing novelpeptide-based drugs to improve the treatment of serious and oftenlife-threatening conditions. Affymax's lead product candidate,Hematide(TM), is currently in Phase 2 clinical trials for thetreatment of anemia associated with chronic renal failure andcancer. For additiona...Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
...ary drug discoveryplatforms to develop ultra-smart drugs that are efficacious and acton select targets. Ari...hnology platformsto synthesize promising candidate drugs for seven targets,including ARI-2243, a lead candidate for DPP-4 inhibition to treattype II diabetes...Other ContentspicaphysicianphysicianphysicianphysicianphysicianphysicianphysicianphysicianphysicianpimplepilespilespilesphytochemicalspimplespimplespinkpinkpinkpinkpinkOther TagsMikroImmuliteVidasOther Tagsupdate 2update 3than 2than 3than 4than 5than 6than 7than 8than 9than 10more 2more 3more 4more 5more 6more 7more 8more 9more 10reveals 2reveals 3reveals 4reveals 5reveals 6reveals 7reveals 8reveals 9
(Date:10/15/2008)...latback turtles dine on fish, shrimp, and mollusks...s green sea turtles. New genetic research carried ...Scientist at the Center for Biodiversity and Conse... and colleagues clarifies our understanding of the...rtle species. , Naro-Maciel and colleagues used ...
(Date:10/15/2008)...on respect for the rights of indigenous peoples an... combat climate change by funding reductions in de... could even unleash a devastating wave of forest l...ed a leading group of forestry and development exp...re gathering in Oslo with policymakers and communi...
(Date:10/15/2008)...study(1) published in the November issue of a scie... published by Oxford Journals on behalf of the Soc...of melamine and cyanuric acid based on research th...mpounds that contaminated pet food in North Americ...k between the pet food contamination that occurred...
(Date:10/15/2008)...brain formation and function may also provide clue...nia are headed toward relapse, researchers say. ,...regularly measuring levels of brain-derived neurot...ith schizophrenia to see if the pattern of their r... headed for trouble, say Medical College of Georgi...
Breaking Biology News(10 mins):Revealing the evolutionary history of threatened sea turtles 2Forest peoples' rights key to reducing emissions from deforestation 2Forest peoples' rights key to reducing emissions from deforestation 3Forest peoples' rights key to reducing emissions from deforestation 4Forest peoples' rights key to reducing emissions from deforestation 5Brain-nourishing molecule may predict schizophrenia relapse 2Brain-nourishing molecule may predict schizophrenia relapse 3Tyco Electronics Contributes 2425 000 Towards Construction of New Fisher House 28TM 29 at Ft Bragg 15331 1Tyco Electronics Contributes 2425 000 Towards Construction of New Fisher House 28TM 29 at Ft Bragg 15331 2Low Acid Coffee Backed By Scientific Research 1606 1Low Acid Coffee Backed By Scientific Research 1606 2Actor robots staff part of new 245M simulation training center 2644 1Actor robots staff part of new 245M simulation training center 2644 2D C Kids Kick Butts on April 2 15324 1D C Kids Kick Butts on April 2 15324 2D C Kids Kick Butts on April 2 15324 3(Date:10/15/2008)... Will Educate Parents about Prescription,Drug Abus...mily Partnership (NFP),has designated Monday, Octo...g off the group,s 23rd annual Red Ribbon Week from...ents with action steps to prevent children,s,presc...million teens in the United States abuse,prescript...
(Date:10/14/2008)...4 /PRNewswire-USNewswire/ -- Kerby T.,Alvy, Ph.D.,...r for the,Improvement in North Hollywood (CICC), h... and Prevention (CDC) to serve as an expert to inf...or the prevention of child,maltreatment., CDC,s n...lationships,(SSNR) as the foundation for a unified...
(Date:10/14/2008)...ker Founder and CEO Andrew Levitt to showcase Heal... Somerville, MA (PRWEB) Octob... , the word-of-mouth marketing (WOM) firm for the ... announced that Andrew Levitt, Founder and CEO of ...Pharma and Health 2.0" at Health 2.0: User-Ge...
(Date:10/14/2008)...PRNewswire-FirstCall/ -- Warner Chilcott,Limited (... its third quarter,2008 financial results prior to... In addition to issuing a press release, the Comp... parties on Monday, November 10, 2008 at,8:00 AM (...e in the call,please dial (877) 856-1955 in the U...
Breaking Medicine News(10 mins):Health News:National Family Partnership Designates October 27th 'Lock Your Meds' Day 2Health News:National Family Partnership Designates October 27th 'Lock Your Meds' Day 3Health News:Los Angeles Psychologist to Help CDC Fight Child Abuse 2Health News:HealthTalker Founder and CEO Andrew Levitt to be Featured at 'Health 2.0: User-Generated Healthcare 2008' 2[0] National Family Partnership Designates October 27th 'Lock Your Meds' Day[0] Los Angeles Psychologist to Help CDC Fight Child Abuse[0] HealthTalker Founder and CEO Andrew Levitt to be Featured at 'Health 2.0: User-Generated Healthcare 2008' [0] Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2008 Financial Results
| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |